OncoMatch/Clinical Trials/NCT05806931
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
Is NCT05806931 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies TAS-102, oxaliplatin, irinotecan with bevacizumab for colon cancer.
Treatment: TAS-102, oxaliplatin, irinotecan with bevacizumab — This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Colorectal Cancer
Biomarker criteria
Required: KRAS mutation
RAS mutation and MMR status must be determined (or tissue availability for testing if not already determined)
Required: NRAS mutation
RAS mutation and MMR status must be determined (or tissue availability for testing if not already determined)
Required: MMR status determined
RAS mutation and MMR status must be determined (or tissue availability for testing if not already determined)
Allowed: KRAS wild-type
antibody therapy with bevacizumab and an anti-EGFR antibody, if RAS wild type, should have been given unless medical reasons have precluded their use
Allowed: NRAS wild-type
antibody therapy with bevacizumab and an anti-EGFR antibody, if RAS wild type, should have been given unless medical reasons have precluded their use
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: antimetabolite (5-FU)
progressed after standard therapy that included 5-FU
Must have received: topoisomerase inhibitor (irinotecan)
progressed after standard therapy that included irinotecan
Must have received: platinum-based chemotherapy (oxaliplatin)
progressed after standard therapy that included oxaliplatin
Must have received: antibody-drug conjugate (bevacizumab)
antibody therapy with bevacizumab ... should have been given unless medical reasons have precluded their use
Must have received: anti-EGFR antibody
antibody therapy with ... an anti-EGFR antibody, if RAS wild type, should have been given unless medical reasons have precluded their use
Cannot have received: (TAS-102)
Participants who have previously received TAS-102
Lab requirements
Blood counts
ANC > 1.5 x 10^9/L; Hemoglobin > 9 g/dL; Platelets > 70 x 10^9/L
Liver function
AST/ALT < 5 x ULN; Albumin within normal limits for institution
Participants with adequate organ function: 1. Absolute neutrophil count (ANC) > 1.5 x 10^9/L 2. Hemoglobin > 9 g/dL 3. Platelets (PLT) > 70 x 10^9/L 4. AST/ALT < 5 x ULN 5. Albumin within normal limits for institution
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Trinitas Hospital and Comprehensive Cancer Center · Elizabeth, New Jersey
- RWJBarnabas Health Jersey City Medical Center · Jersey City, New Jersey
- RWJBarnabas Health - Monmouth Medical Center Southern Campus · Lakewood, New Jersey
- Cooperman Barnabas Medical Center (Saint Barnabas Medical Center) · Livingston, New Jersey
- RWJBarnabas Health - Monmouth Medical Center · Long Branch, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05806931 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS mutation is a required biomarker for enrollment.
Does this trial require MMR?
Yes, MMR status determined is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages